SPTBN1

BullFrog AI Launches Preclinical Study to Investigate BF-114’s Potential in Battling Obesity

Retrieved on: 
Wednesday, December 6, 2023
NAFLD, Risk, NASH, MOA, Non-alcoholic fatty liver disease, Small RNA, Michigan Medicine, Diabetes, Bullfrog, Obesity, University, Fatty liver disease, University of Michigan, DSM-IV codes, Artificial intelligence, Machine learning, SPTBN1, Medical device

GAITHERSBURG, Md., Dec. 06, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the launch of a preclinical study to evaluate the efficacy of its drug candidate BF-114 in obesity. The study, which will be conducted in collaboration with Randy Seeley, Ph.D., the Henry King Ransom Endowed Professor of Surgery at Michigan Medicine, the academic medical center of University of Michigan, and Director of the Michigan Nutrition Obesity Research Center, is designed to evaluate the ability of BF-114 to modulate obesity in an established animal model and to elucidate the mechanism of action (MOA). The study is expected to be completed in the second quarter of 2024 and will complement internal activities that leverage the Company’s AI platform to identify and address new pathways for targeting obesity and metabolic diseases.

Key Points: 
  • The study is expected to be completed in the second quarter of 2024 and will complement internal activities that leverage the Company’s AI platform to identify and address new pathways for targeting obesity and metabolic diseases.
  • Obesity affects over 40% of the US population and is associated with increased risk of heart disease and diabetes.
  • Medical care costs for obesity-related health problems were estimated to be in excess of $170 billion in 2019.
  • “The market for obesity drugs is projected to exceed $77 billion by 2030 , and pharmaceutical companies around the world have recognized the importance of targeting multiple pathways to treat this condition,” said Vin Singh, CEO of BullFrog AI.

Feinstein Institutes Researchers Identify New Molecular Targets to Curb Obesity, Fatty Liver Diseases

Retrieved on: 
Wednesday, December 15, 2021
Research, Hospitals, Diabetes, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Susan, LinkedIn, Lipid, NAFLD, Non-alcoholic fatty liver disease, TGF, Science Translational Medicine, Fatty liver disease, Clinical trial, Cancer, Credit, NASH, Science, Medical research, Lists of diseases, Genetics, Institute, Feinstein Institute for Medical Research, CEO, Research, Northwell Health, Patient, 3D, Disease, Molecular medicine, Mental health, Obesity, SPTBN1, Medicine, Multimedia, Autoimmunity, Mouse, Heart, Dietary supplement, Hospital, Medical device, MD

To address this issue and help reduce obesity and the development of fatty liver diseases, scientists at The Feinstein Institutes for Medical Research identified new molecular targets that could lead to future treatment.

Key Points: 
  • To address this issue and help reduce obesity and the development of fatty liver diseases, scientists at The Feinstein Institutes for Medical Research identified new molecular targets that could lead to future treatment.
  • View the full release here: https://www.businesswire.com/news/home/20211215006027/en/
    Lopa Mishra, MD, co-director of the Institute of Bioelectronic Medicine at the Feinstein Institutes.
  • (Credit: The Feinstein Institutes)
    The research, led by Lopa Mishra, MD , co-director for the Institute of Bioelectronic Medicine at the Feinstein Institutes, was published in Science Translational Medicine .
  • Dr. Mishras leadership in revealing basic molecular mechanisms of liver disease bridges the gap between her lab and a patients bedside.

Scientists Find Genetic Cause, Underlying Mechanisms of New Neurodevelopmental Syndrome

Retrieved on: 
Wednesday, July 7, 2021
Mental health, Health, Genetics, Other Health, Other Science, Research, Science, Cytoskeleton, Spectrin, SPTBN1

The gene SPTBN1 instructs neurons and other cell types how to make II-spectrin, a protein with multiple functions in the nervous system.

Key Points: 
  • The gene SPTBN1 instructs neurons and other cell types how to make II-spectrin, a protein with multiple functions in the nervous system.
  • Identification of the genetic variants that cause this broad spectrum of disabilities is the first important milestone to finding treatments for this syndrome.
  • Identifying the genetic cause of rare diseases such as the SPTBN1 syndrome requires pooling knowledge from several patients to establish common clinical and biological patterns.
  • It is exciting to be part of such important work with a team of dedicated scientists and clinicians.